Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 10;11(3):2102089. doi: 10.1002/adhm.202102089

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Wiley‐VCH GmbH

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Schematic representation of the manufacture of SARS‐CoV‐2 antigen‐coated BPs. An endotoxin free production strain of Escherichia coli, ClearColi BL21(DE3), was bioengineered to produce SARS‐CoV‐2 antigen‐coated BPs in one step. BPs coated with glycosylated S1 (S1‐ICC‐BP) were generated in two steps by irreversible SpyCatcher/SpyTag (SpyC/SpyT) ligation between BP‐SpyC, produced by ClearColi BL21(DE3), and glycosylated spike protein (S1‐ICC), produced using baculovirus expression in insect cell culture (ICC). Immunogenicity of various SARS‐CoV‐2 antigen‐coated BPs was analyzed in a mouse model and the two best performing vaccine candidates were evaluated in the hamster SARS‐CoV‐2 challenge model.